CURRICULUM VITAE
Personal Information:
Name: Maowen Ba
Gender: Male
Date of birth: January 1978
Place of birth: Zibo, Shandong, China
Nationality: China
Marital status: Married
Department:Department of Neurology, Yantai Yuhuangding Hospital, affiliated To Qingdao medical University,Shandong Province, 264000, China
Address: No.20, YudongRoad , Yantai City , Shandong Province, China
E-mail: bamaowen@163.com
Education:
2004~2007, Ph.D. Shanghai jiaotong University, Shanghai, China
2001~2004, M.D.Shanghai Second Medical University, Shanghai, China
Employment:
2014~present, Associate chief doctor, Dept. of Neurology, Yuhuangding Hospital
Affiliated To Qingdao medical University, Shandong, China
2007~2013,Attending doctor, Dept. of Neurology, Yuhuangding Hospital
Affiliated To Qingdao medical University, Shandong, China
Honors and Awards:
The prize of Yantai scientific and Technological Progress Award (2015)
The prize of Yantai scientific and Technological Progress Award (2013)
The prize of Yantai scientific and Technological Progress Award (2012)
The sixth Yantai Youth Science and Technology Award (2012)
The young technology pacesetter of Yantai Yuhuangding Hospital (2012, 2013)
Medical science and technology award of Shanghai City (2009)
Shanghai jiaotong UniversityOutstanding doctoral graduates (2007)
Shanghai jiaotong University Graduate Scholarship (2007)
Current Research:
Clinical study of effect and safety of rasagilinemesylate orally disintegrating tablets
in the treatment of Parkinson’s disease patients with motor fluctuations.
Mitochondrial mechanism in the Parkinson’s disease and Alzheimer's disease and the
related neuroprotective effects.
Synaptic plasticity, Parkinson’s disease and levodopa-induced motor complications.
Focus on NMDA and AMPA signaling complex and synaptic plasticity.
Publications:
(1) Kong M, Ba M, Liu C, et al. NR2B antagonist CP-101,606 inhibits NR2B
phosphorylation at tyrosine-1472 and its interactions with Fyn in
levodopa-induced dyskinesia rat model. Behav Brain Res. 20151;282:46-53.
（Corresponding author）
(2) Ba M, Kong M, Ma G. Postsynaptic density protein 95-regulated NR2B tyrosine
phosphorylation and interactions of Fyn with NR2B in levodopa-induced
dyskinesia rat models. Drug Des Devel Ther. 2014 Dec 19;9:199-206.
(3) Kong M, Ba M. Protective effects of diazoxide against Aβ 25-35 -induced PC12 cell
apoptosis due to prevention of endoplasmic reticulum stress. Neuroreport. 2012;
23(8):493-7.（Corresponding author）
(4) Kong M, Ba M, Liang H, Ma L, Yu Q, Yu T, Wang Y. 5’-aza-dC sensitizes
paraquat toxic effects on PC12 cell. NeurosciLett. 2012, 524(1):35-39.
（Corresponding author）
(5) Ba M, Kong M, Yu G, et al. GluR1 phosphorylation and persistent expression of
levodopa-induced motor response alterations in the Hemi-Parkinsonian rat.
Neurochem Res. 2011, 36(6):1135-1144.
(6) Kong M, Ba MW, Song L, et al. Comparative effects of acute or chronic
administration of levodopa to 6-OHDA-lesioned rats on the expression and
phosphorylation of N-methyl-D-aspartate Receptor NR1 subunits in the striatum.
Neurochem Res. 2009,34:1513–1521.(co-first author)
(7) Maowen Ba, Min Kong, Guozhao Ma, et al. Cellular and behavioural effects of
5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor
complications. Brain Research. 2007,1127(1):177-184.
(8) Hong-Qi Yang, Mao-Wen Ba, Ru-Jing Ren, et al. Mitogen activated protein
kinase and protein kinase C activation mediate promotion of sAPPalpha secretion
by deprenyl. Neurochem Int. 2007,50(1):74-82
(9) Maowen Ba, Min Kong, Hongqi Yang, et al. Changes in Subcellular Distribution
and Phosphorylation of GluR1 in Lesioned Striatum of 6-OHDA-Lesioned and
L-dopa-Treated Rats. Neurochem Res. 2006, 31(11):1337-1347.
(10) Maowen Ba, Min Kong. Clinical progress
ofParkinsondisease and motor complications. Chemical Industry Press.2012.
Peking. ISBN:978-7-122-13553-7.
Grants:
(1) The Young Scholars General Program of National Natural Science Foundation of
the People’s Republic of China (Project proposal No. 81100954). (The first
responsible person, 2012-2014)
(2) The General Program of National Natural Science Foundation of the People’s
Republic of China (Project proposal No. 81571234). (The first responsible person,
2016-2019)
